Literature DB >> 12625573

Hearing deterioration in patients with a non-growing vestibular schwannoma.

Kees Graamans1, Johannes E Van Dijk, Luuc W Janssen.   

Abstract

OBJECTIVE: The aim of this study was to document and analyse the course of several audiometric parameters in 49 patients with a non-growing unilateral vestibular schwannoma (VS).
MATERIAL AND METHODS: Patients received conservative management and absence of tumour growth was ascertained by means of serial magnetic imaging studies. Pure-tone audiometry and speech audiometry were performed at yearly intervals.
RESULTS: Pure-tone audiometry revealed a significant increase in thresholds at all frequencies, except for 8.0 kHz. The maximum yearly threshold increase was 2.4 dB hearing level at 1.0 and 2.0 kHz. Speech audiometry revealed a significant decrease in maximum discrimination over the course of time. No significant changes were observed in the following parameters: the intensity level at which maximum discrimination was achieved; the roll-over index; the speech reception threshold; and the slope of the curve in the speech audiogram. No change was observed in the relation between pure-tone audiometry thresholds and speech audiometry scores. Apparently, the deterioration of pure-tone perception and speech discrimination ran parallel courses.
CONCLUSIONS: The results of this study indicate that hearing loss is a predominant symptom in patients with a non-growing VS, as is also known in patients with a growing lesion. Moreover, it seems unlikely that the hearing loss in VS patients is merely the result of mechanical influences on retrocochlear neural or vascular structures.

Entities:  

Mesh:

Year:  2003        PMID: 12625573     DOI: 10.1080/0036554021000028075

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  9 in total

1.  Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.

Authors:  Yingchao Zhao; Pinan Liu; Na Zhang; Jie Chen; Lukas D Landegger; Limeng Wu; Fu Zhao; Yanxia Zhao; Yanling Zhang; Jing Zhang; Takeshi Fujita; Anat Stemmer-Rachamimov; Gino B Ferraro; Hao Liu; Alona Muzikansky; Scott R Plotkin; Konstantina M Stankovic; Rakesh K Jain; Lei Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-09       Impact factor: 11.205

2.  Change in hearing and tinnitus in conservatively managed vestibular schwannomas.

Authors:  Nicola Quaranta; David M Baguley; David A Moffat
Journal:  Skull Base       Date:  2007-07

3.  Hearing improvement in a growing vestibular schwannoma.

Authors:  Marcos Martinez Del Pero; Simon K W Lloyd; David A Moffat
Journal:  Skull Base       Date:  2009-03

4.  Hearing preservation surgery in acoustic neuroma. Slow progress and new strategies.

Authors:  A Mazzoni; F Biroli; C Foresti; A Signorelli; C Sortino; E Zanoletti
Journal:  Acta Otorhinolaryngol Ital       Date:  2011-04       Impact factor: 2.124

5.  Hearing preservation surgery in acoustic neuroma: long-term results.

Authors:  A Mazzoni; E Zanoletti; V Calabrese
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-04       Impact factor: 2.124

6.  Current Understanding of Hearing Loss in Sporadic Vestibular Schwannomas: A Systematic Review.

Authors:  Jinlu Gan; Yanling Zhang; Jingnan Wu; Deqiang Lei; Fangcheng Zhang; Hongyang Zhao; Lei Wang
Journal:  Front Oncol       Date:  2021-08-12       Impact factor: 6.244

7.  Mechanisms of hearing loss in neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Raul A Vasquez; John A Butman; Tianxia Wu; Keaton Morgan; Carmen C Brewer; Kelly King; Chris Zalewski; H Jeffrey Kim; Russell R Lonser
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

8.  Spontaneous shrinkage of vestibular schwannoma.

Authors:  Rossana Romani; Jonathan Pollock
Journal:  Surg Neurol Int       Date:  2016-05-19

Review 9.  Hearing Restoration in Neurofibromatosis Type II Patients.

Authors:  Jeon Mi Lee; Jin Woo Chang; Jae Young Choi; Won Seok Chang; In Seok Moon
Journal:  Yonsei Med J       Date:  2016-07       Impact factor: 2.759

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.